Kewei Wang: Cutting-edge Insights at 2013 Symposium

Kewei Wang: Cutting-edge Insights at 2013 Symposium

Table of Contents:

1. Introduction
2. The Structure and Function of Voltage-Gated Potassium Channels 2.1 Voltage-Gated Potassium Channels: A Brief Overview 2.2 Key Components and Subunits of Voltage-Gated Potassium Channels 2.3 The Role of Voltage-Gated Potassium Channels in Neuronal Function
3. Understanding Neurological Disorders 3.1 Neuropsychiatric Disorders: An Introduction 3.2 Molecular Mechanisms Implicated in Neurological Disorders 3.3 Potential Therapeutic Approaches for Neurological Disorders
4. Targeting Voltage-Gated Potassium Channels for Therapeutic Potential 4.1 The Importance of Targeting Voltage-Gated Potassium Channels 4.2 Identifying Pharmacological Agents for Potential Therapy 4.3 Screening Channel Modulators from Natural Resources 4.4 Compounds and Toxins for Gated Ion Channels
5. The Role of Casing Q in Neuropsychiatric Disorders 5.1 Understanding the Structure of Casing Q 5.2 The Interaction Model of Casing Q and Other Subunits 5.3 The Functional Differences of Casing Q in Neuronal Excitability
6. The Development of Potassium Channel Modulators 6.1 Solving the Crystal Structure of Kv4 and KChIP1 6.2 Exploring the Unique Features of Kv3 6.3 Intracellular Protons and the Activation of Potassium Channels
7. Screening and Testing Potassium Channel Modulators 7.1 Stable Cell Lines for Testing Modulators 7.2 High-Throughput Screening of Compounds 7.3 Testing Selectivity and Efficacy in Patch-Clamp Recordings
8. In Vivo Pharmacology and Efficacy 8.1 Pharmacokinetics and Half-Life of Potassium Channel Modulators 8.2 Testing the Efficacy in Epilepsy and Pain Models 8.3 Potential Applications and Indications for Potassium Channel Modulators
9. Conclusion
10. FAQs

The Role of Voltage-Gated Potassium Channels in Neuropsychiatric Disorders

Neuropsychiatric disorders, such as epilepsy, schizophrenia, and Attention deficit disorders, are characterized by abnormal neuronal excitability. Understanding the underlying molecular mechanisms of these disorders is crucial for identifying potential therapeutic targets. In recent years, there has been growing interest in the role of voltage-gated potassium channels in neurological diseases.

Voltage-gated potassium channels, specifically the casing Q subtype (Kv7.2), have been found to play a significant role in neuronal excitability and neurotransmission. These channels, which are highly expressed in the brain, regulate the firing of action potentials and control the repetitive firing of neurons. Dysregulation of these channels has been implicated in various neuropsychiatric disorders.

Recent research has focused on identifying pharmacological agents that can modulate the activity of voltage-gated potassium channels for potential therapeutic use. Screening of compounds from natural resources, such as toxins and plant extracts, has led to the discovery of Novel modulators that can selectively activate or block the casing Q channel.

In preclinical studies, these potassium channel modulators have shown promising results in reducing neuronal hyperexcitability and reversing the symptoms associated with epilepsy and pain. Furthermore, their potential applications extend beyond these indications, with the possibility of addressing memory and cognitive impairments in conditions like Alzheimer's disease.

In conclusion, the identification of selective modulators for voltage-gated potassium channels opens up new avenues for the development of targeted therapies for neuropsychiatric disorders. Further research is needed to validate the efficacy of these compounds and explore their potential in other neurological conditions.